Skip to main content
Fig. 12 | Journal of Experimental & Clinical Cancer Research

Fig. 12

From: Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Fig. 12

Whole genome methylation analysis of tumors. A Scatter plot showing the samples’ coordinates on principal component analysis for all conditions, treatments containing guadecitabine (Guad) = green dots, treatments without guadecitabine (W/O Guad) = ochre triangles. The two treatment conditions are clearly separated by the first two principle components. B Scatterplots are shown for samples treated with ICBs alone or triple therapy analyzed by hybridization to Infinium Mouse Methylation BeadChip arrays (Illumina) according to the best combined ranks of signals (scale: mean beta values) derived from all methylation sites (tiling), CpG-islands, and genomic regions containing genes and promoter regions. Blue clouds contain the majority of single methylation sites that are not differentially methylated in a statistically significant manner, red dots indicate sites that are differentially methylated in a significant manner, blue dots correspond to borderline significant sites. Blue clouds show a bimodal distribution of high and low methylation with only a minor population of sites of intermediate methylation, especially so for CpG-islands and promoters

Back to article page